 Connection
Jennifer Guimbellot to Quinolines
This is a "connection" page, showing publications Jennifer Guimbellot has written about Quinolines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.512 |
|
|
|
-
Guimbellot JS, Chalamalla A, Baker E, Ryan KJ, Dowell A, Abouelenein S, Bartlett LE, Bergeron J, Turner G, Acosta EP, Ramos KJ. Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant. J Cyst Fibros. 2025 May; 24(3):534-541.
Score: 0.233
-
Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024 Sep; 86:102301.
Score: 0.220
-
Harris WT, Baker EH, Guimbellot JS, Collaco JM, Schechter MS, Oates GR. Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis. J Cyst Fibros. 2025 Sep; 24(5):957-962.
Score: 0.059
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|